Abiraterone acetate (AA) administered with food may help to reverse PSA progression in men with metastatic castration-resistant prostate cancer (mCRPC), according to a small study published in Prostate Cancer and Prostatic Diseases.

Researchers from Duke University retrospectively looked at medical records of men with mCRPC who received AA from April 2011 to December 2013 in order to measure the percentage of those who had any decline in PSA levels within three months of changing administration to with or without food.

In total, they included 19 men who switched from AA administration from without to with food, as well as 41 patients who were administered AA without food only.

RELATED: Addition of Lenalidomide to Docetaxel, Prednisone Not Effective for mCRPC

Among those patients, a decline in PSA was found in 3 of the 19 men who began to take AA with food at progression. They also found a decline in testosterone levels in five out of seven patients from pre-food levels, with no change in toxicity in any patients.

“Further prospective comparative studies are needed to determine if changing AA administration is beneficial,” the authors concluded.

Reference

  1. Stover, JT, et al. “Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.” Prostate Cancer and Prostatic Diseases. doi: 10.1038/pcan.2015.7. [epub ahead of print]. March 17, 2015.